SBIR/STTR Research Award
Development of SAgA Therapy for clearance of NMO-IgG in patients with neuromyelit
Award amount
$220,834Program and phase
SBIR · Phase IAward year
2014Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Orion BioScience Inc
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- Not reported
- Solicitation number
- PA13-234
- Topic code
- NEI
Research abstract
DESCRIPTION (provided by applicant): Orion BioScience Inc. has developed a Soluble Antigen Array (SAgA) therapeutic that displays multiple copies of aquaporin-4 epitope for targeted clearance of the auto reactive NMO-IgG antibody in patients with neuromyelitis optica (NMO). The product is intended to selectively clear NMO-IgG while limiting interaction with other non-NMO specific antibodies, thereby reducing side effects often seen with global immunosuppressants. Orion's SAgA technology displays multiplecopies of AQP4 epitope along a flexible polymer backbone and will initiate endogenous reticuloendothelial clearance mechanisms through antibody agglomeration. Blindness is the primary clinical outcome of NMO induced attacks; however, severe attacks can also lead to extensive transverse myelitis and paralysis. The ten year mortality rate after initial diagnosis in patients with NMO is gt25%, however, no dedicated NMO therapeutic is available. A majority of symptoms result from the binding of NMO-IgG to AQP4,
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Humidifeye Plug for Dry Eye Disease
- A Novel Therapeutic to Promote Corneal Repair
- Drug Screening Platform in the Light-Responsive Human Eye
- RetiVue EntireEye - A Handheld, High-Resolution, Non-Contact, One Image, Widefield Retinal Screening Camera for Premature and Healthy Newborn Babies
- The iD2: A Smart Eye Drop Cap Monitor for Eye Drop Adherence